Eli Lilly presented data from several studies of tirzepatide, an investigational dual gastric inhibitory polypeptide and glucagonlike peptide1 receptor agonist, that showed its potential to treat metabolic conditions including type 2 diabetes and nonalcoholic steatohepatitis.
“We are excited about tirzepatide’s potential to make an important impact on people with type 2 diabetes and other conditions, including obesity and NASH,” Brad Woodward, MD, global development leader of incretins at Lilly, said in a press release. “The tirzepatide results seen in early and mid-stage trials pave the way for our extensive phase 3 programs, reinforce our commitment to researching it further across different populations and support its potential of addressing an unmet treatment need.”
From the phase 2 studies, tirzepatide improved markers of beta cell function and insulin sensitivity in patients with type 2 diabetes and consistent positive impact on blood glucose control (HbA1c reductions up to 2%) and weight loss (up to 5.7 kg) while improving tolerability with dose escalations.
Results from a subanalysis also showed that treatment with tirzepatide led to improvements in NASH-related markers.
Treatment-related adverse events were mild to moderate in intensity and overall less common than in previous studies. Discontinuation rates due to adverse events were less than 5% compared with placebo.